Clinical outcome for patients with intermediate- or high-risk prostate cancer treated with prostate permanent seed implantation

DOI Web Site 13 References
  • Fukumori Tomoharu
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Nakatsuji Hiroyoshi
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Furutani Shunsuke
    Department of Radiology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Fukawa Tomoya
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Takemura Masahiko
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Yamamoto Yasuyo
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Yamaguchi Kunihisa
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Kishimoto Tomoteru
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Izaki Hirofumi
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Takahashi Masayuki
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Ikushima Hitoshi
    Department of Radiology, Institute of Health Biosciences, The University of Tokushima Graduate School
  • Kanayama Hiro-omi
    Department of Urology, Institute of Health Biosciences, The University of Tokushima Graduate School

Bibliographic Information

Other Title
  • 中間リスク群，高リスク群前立腺癌に対するI-125密封小線源療法の治療成績
  • チュウカン リスクグン,コウリスクグン ゼンリツセンガン ニ タイスル I-125 ミップウ ショウセン ゲン リョウホウ ノ チリョウ セイセキ

Search this article

Description

  We evaluated clinical outcomes in patients with intermediate- or high-risk prostate cancer treated using 125I brachytherapy. From 2003 to 2009, patients with 76 intermediate-risk and 33 high-risk prostate cancers as defined by the D’Amico risk classification were treated using 125I permanent prostate brachytherapy. Mean duration of follow-up was 37.2 months（range, 24-60 months）. Neoadjuvant hormone therapy（NHT）was administered to 72 patients, including 58 patients treated with complete androgen blockade for 6 months. Biochemical relapse rates in patients with intermediate and high risk using Phoenix definitions were 6.6% and 9.1%, respectively. NHT had no significant impact on biochemical relapse rates in patients with intermediate- and high-risk prostate cancer. A significant difference in the dose delivered to 90% of the prostate gland（D90）was seen from dose-volume histograms between the PSA failure group and the non-PSA failure group（135.1 Gy vs 158.3 Gy, p=0.036）. Radiation dose is an important factor associated with biochemical failure.

Journal

References(13)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top